TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers.
Colon cancers frequently harbor KRAS mutations, yet only a subset of KRAS mutant colon cancer cell lines are dependent upon KRAS signaling for survival. In a screen for kinases that promote survival of KRAS-dependent colon cancer cells, we found that the TAK1 kinase (MAP3K7) is required for tumor cell viability. The induction of apoptosis by RNAi-mediated depletion or pharmacologic inhibition of TAK1 is linked to its suppression of hyperactivated Wnt signaling, evident in both endogenous and genetically reconstituted cells. In APC mutant/KRAS-dependent cells, KRAS stimulates BMP-7 secretion and BMP signaling, leading to TAK1 activation and enhancement of Wnt-dependent transcription. An in vitro-derived "TAK1 dependency signature" is enriched in primary human colon cancers with mutations in both APC and KRAS, suggesting potential clinical utility in stratifying patient populations. Together, these findings identify TAK1 inhibition as a potential therapeutic strategy for a treatment-refractory subset of colon cancers exhibiting aberrant KRAS and Wnt pathway activation.
Pubmed ID: 22341439 RIS Download
Adenomatous Polyposis Coli Protein | Animals | Apoptosis | Bone Morphogenetic Proteins | Cell Line, Tumor | Cell Nucleus | Colonic Neoplasms | Gene Expression Profiling | Germ-Free Life | Humans | Intracellular Signaling Peptides and Proteins | Mice | Mutation | Neoplasm Transplantation | Proto-Oncogene Proteins | RNA Interference | Signal Transduction | Transcriptional Activation | Transplantation, Heterologous | Tumor Cells, Cultured | Wnt Signaling Pathway | beta Catenin | ras Proteins